Jennifer Sprague, M.D., Ph.D.  sprague_j@kids.wustl.edu

Instructor in Pediatrics, Endocrinology and Diabetes
Endocrinology and Diabetes

phone: (314) 454-6051

Clinical Interests

Dr. Sprague’s clinical interests include pediatric diabetes (type 1 and type 2) and general endocrine disorders (disorders of growth, puberty, thyroid and adrenal disease). She has a particular interest in endocrine complications of obesity including type 2 diabetes, metabolic syndrome and polycystic ovary syndrome (PCOS). Dr. Sprague is active in the type 2 diabetes education and care program at St. Louis Children’s Hospital. She has a focus on patient education, patient centered outcomes and quality improvement.

Education

  • BS, Highest Honors, Indiana University2000
  • MD, Washington University School of Medicine2007
  • PhD, Washington UNiversity School of Medicine2007

Training

  • Pediatrics Residency, St. Louis Children's Hospital2007 - 2010
  • Pediatric Endocrinology Fellowship, Washington University2010 - 2013

Licensure and Board Certification

  • MO, Medicine 2010
  • General Pediatrics 2010
  • Pediatric Endocrinology 2013

Honors

  • National Starch & Chemical Scholarship1997 - 1998
  • Lubrizol Scholarship in Chemistry1998 - 1999
  • Ronald E. McNair Post-baccalaureate Achievement Program1999 - 2000
  • Triple Crown Award - St. Louis Children's Hospital, Children's Direct2012
  • Best Abstract in Basic Research - Department of Pediatrics Research Retreat2013

Recent Publications view all (8)


Publication Co-Authors

  1. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One. 2013;8(1):e54625. doi:10.1371/journal.pone.0054625  PMCID:PMC3551761  PMID:23349943 
  2. Vitamin D suppression of endoplasmic reticulum stress promotes an antiatherogenic monocyte/macrophage phenotype in type 2 diabetic patients. J Biol Chem. 2012;287(46):38482-94. doi:10.1074/jbc.M112.386912  PMCID:PMC3493893  PMID:23012375 
  3. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev. 2011;9(1):463-73; quiz 474-5. PMID:22783644 
  4. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases. J Nucl Med. 2009;50(11):1873-80. doi:10.2967/jnumed.109.067140  PMCID:PMC2836828  PMID:19875645 
  5. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents. J Med Chem. 2007;50(10):2527-35. doi:10.1021/jm070204r  PMID:17458949 
  6. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med. 2007;48(2):311-8. PMCID:PMC2711534  PMID:17268030 
  7. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol. 2006;33(2):227-37. doi:10.1016/j.nucmedbio.2005.10.011  PMID:16546677 
  8. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10(24):8674-82. doi:10.1158/1078-0432.CCR-04-1084  PMID:15623652 
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130